[www] [BibTex]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.

[www]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.

[www] [BibTex]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.

[www]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.

[www]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.

[www] [BibTex]

Note: inproceedings

Abstract: Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical applications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alternative to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.